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Introduction  
Cancer is a terrible disorder facing human today and 
unfortunately, lack of deep knowledge about cancer 
biology causes perfect treatment failing. However, 
several strategies have been developed upon recent 
findings in molecular biology. One of these approaches 
appears to be valuable because of inhibiting inter-
cellular gap junction communication (GJIC) between 
cells. As a rule, lack of gap junctions was commonly 
observed in carcinogenesis (Leithe et al. 2006). Some 
critical small biomolecules like cAMP and Ca2+ as well 
as several small sized amino acids could pass through 
this communicative channel. Cellular apoptosis pathway, 
Akt signaling pathway, EGF pathway, p53 pathway, 
inhibition of matrix metalloproteinases (MMPs) and 
VEGF family ligands and receptors are the most 
important biomolecules and ways in cancer biology 
which could be affected by these small agents. As 
mentioned, EGF pathway and its obedience 
biomolecules has vital role in carcinogenesis of 
epithelial derived carcinomas like breast and lung 
cancers (Cameron et al. 2003). This cell-surface tyrosine 
kinase receptor is a member of the ErbB family of 
receptors and mutations which could result in some 
epithelial derived carcinomas including breast cancer 
through affecting its expression or activity. EGFR over 
expression was reported in 20% - 50% of breast cancer 
(Agelaki et al. 2009). EGFR is activated by binding its 
specific ligands, including epidermal growth factor 
(EGF) and transforming growth factor α (TGFα). Due to 
activation by its ligands, EGFR switches from an 
inactive monomeric form to an active homodimer (Dong 
J and Wiley HS 2000). Several signal transduction 
cascades was initiated by downstream signaling proteins, 
principally the mitogen-activated protein kinase 
(MAPK), phosphatidylinositol-3-kinase (PI-3K/Akt), 
and finally signal transducer and activator of 
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Introduction: Gap junctions play an important role in the cell proliferation in mammalian 
cells as well as carcinogenesis. However, there are controversial issues about their role in 
cancer pathogenesis. This study was designed to evaluate genotoxicity and cytotoxicity of 
Carbenoxolone (CBX) as a prototype of inter-cellular gap junction blocker in MCF7 and 
BT20 human breast cancer cells. Methods: The MCF7and BT20 human breast cancer cell 
lines were cultivated, and treated at designated confluency with different doses of CBX. 
Cellular cytotoxicity was examined using standard colorimetric assay associated with cell 
viability tests. Gene expression evaluation was carried out using real time polymerase 
chain reaction (PCR). Results: MCF7 and BT20 cells were significantly affected by CBX 
in a dose dependent manner in cell viability assays. Despite varying expression of genes, 
down regulation of pro- and anti-apoptotic genes was observed in these 
cells.  Conclusion: Based upon this investigation, it can be concluded that CBX could 
affect both low and high proliferative types of breast cancer cell lines and disproportionate 
down regulation of both pre- and anti-apoptotic genes may be related to interacting 
biomolecules, perhaps via gap junctions.  
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transcription (STAT) pathways (Loew et al. 2009; Afaq 
et al. 2008; Camp et al. 2005; Mamot and Rochlitz. 
2006) which mainly undergoes to cell proliferation, 
adhesion and migration (Agelaki et al. 2009) as well as 
involvement in the metastasis, angiogenesis and 
apoptosis inhibition (Gialeli et al. 2009; Camp et al. 
2005).  In regards to these miscellaneous biomolecules, 
it is believed that EGFR signal transduction could be 
modulated by potent small molecules which may be 
transferred via gap junctions and could prevent or 
promote pathogenesis of cancer (Nicholson 2003). CBX 
(C34H50O7) [3-(3-carboxy-1-oxopropoxy)-11-oxo-
Olean-12 en-29-oic acid] (Fig. 1) as prototypic inter-
cellular communication blocker which mediated via Gap 
junctions, inhibits cell growth and induces apoptosis in 
several types of cancer. CBX is a semi-synthetic 
derivation of Glycyrrhizin obtained from Licorice root 
and demonstrates a superficial resemblance to steroid 
structures. This drug is often used as a gap junction 
inhibitor in cells (Ye, Z. C., et al. 2003; Li, J., et al. 
2001). However, there are some controversial issues 
about gap junction role in carcinogenesis(Cronier, 
Crespin et al. 2009). This study was designed to 
determine the impacts of CBX on MCF7and BT20 
human breast cancer cells in the view of cell growth and 
apoptosis particularly at mRNA transcriptomics level. 
 
 
      
 
 
 
 
Fig. 1. The structure of carbenoxolone (CBX). 
 
Materials and methods 
Materials 
The MCF7 and BT20 human breast cancer cell lines, 
Cell culture plates and flasks were obtained from 
National cell bank of Iran (Pasteur institute, Iran) and 
IWAKI, Japan respectively. RPMI1640 medium, 
Trypsin-EDTA (0.05%–0.02%), Tri-Reagent, 
Dithiotheritol (DTT), first strand reverse transcriptase 
(RT) buffer, Moloney murine leukemia virus reverse-
transcriptase (MMLV-rt, 200U/l) was purchased from 
Sigma Aldrich Co., (Poole, UK). Agarose and Fetal 
bovine serum (FBS) were bought from Gibco, Invitrogen 
(Paisley, UK). Ribonuclease inhibitor was obtained from 
Fermentas, Canada. STAT1, AKT1, GAPDH 
(Glyceraldehyde 3-phosphate dehydrogenase), TP53, 
BCL2 (B-cell lymphoma 2) and CYCS (Cytochrome c) 
Forward and reverse oligonucleotide primers were 
provided from MWG-Europhin, (Ebersberg, Germany). 
The SYBR Green PCR Master Mix was obtained from 
Applied Biosystems, Foster City, USA. Diethyl 
pyrocarbonate (DEPC) treated water; streptomycin and 
Penicillin G were obtained from CinnaGen, (Tehran, 
Iran). Taq DNA polymerase, polymerase chain reaction 
(PCR) reaction buffer, Random hexamer primers 
(pdN6), deoxynucleotide triphosphate monomers 
(dNTPs) and MgCl2 were obtained from QIAGEN 
(Crawley, UK). Carbenoxolone was obtained from 
Sigma Aldrich Co., (Poole, UK). All other chemicals not 
mentioned above were in the highest quality available. 
Cell culture 
The MCF7and BT20 human breast cancer cells were 
seeded on 6-well plates at a density of 4.0×104 
cells/cm2. These cells were saved in a humidified 
incubator (95% air and 5% CO2) at 37˚C. Cell culture 
media consisted of RPMI 1640 complemented with 10% 
FBS, penicillin G (200 U/ml) and streptomycin (200 
g/ml). CBX was solved in RPMI 1640 media at 
concentrations of 50M, 100M, 150M, 300M, 
600M and finally 1000M (1Mm) and then cells were 
lay open to viability examinations as well as gene 
expression profiling using real time RT-PCR. 
Cell viability assessment  
The cultured MCF7and BT20 human breast cancer cells 
at 40–50% confluency were subjected to MTT assay in 
the 96-well plates. The cells were treated with a range of 
CBX concentrations and each group were incubated for 
24 and 48 hours at 37˚C. After which, the cells of each 
group were washed once with phosphate buffered saline 
(PBS) and culture medium was replaced with 150 l 
fresh media and then 50 l MTT reagent (2 mg/ml in 
PBS) was added to each well. After a 4 hr incubation 
with MTT at 37˚C, medium was removed and the cells 
were exposed to 200 l DMSO and 25 l of Sorenson 
buffer (0.1 M glycine, 0.1 M NaCl, pH 10.5). The 
cultures were incubated for 30 min at 37˚C for formazan 
crystals dissolving and then UV absorbance was 
measured at 570 nm using a spectrophotometric plate 
reader, ELx 800 (Biotek, CA, USA). Trypan blue 
exclusion test was performed for growth inhibition 
assessment of CBX. Briefly, cells were counted based on 
the ability of cells to exclude trypan blue dye using a 
hemocytometer for obtaining vital cell numbers versus 
death cell numbers. Light microscopic examinations 
were conducted for morphological assessments using 
Olympus invert microscope CKX41 equipped with 
Olympus DP20 camera and CellA 3.3 software 
(Olympus optical Co., Ltd., Tokyo, Japan). 
Gap junctions in cancer cells 
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Gene expression analysis 
Cells were subjected to gene expression evaluation just 
at 150M which was obtained as IC50 of CBX at the 
exposure time of 24 hr and total RNA was isolated using 
TriReagent according to manufacturer guideline. The 
quality and quantity of the extracted RNA was measured 
respectively by electrophoresis and NanoDrop®1000 
Spectrophotometer (Nano- Drop Technologies, 
Wilmington, DE, USA). Primers were designed from 
published Gene Bank sequences using Beacon Designer 
5.01 (Premier Biosoft International, 
http://www.premierbiosoft.com) and listed in Table 1. 
The reverse transcription reaction was performed using 
11 l DEPC treated water, 4 l MMLV buffered with 
DTT, 2 l dNTPs (10 mM), 0.5 l pdN6 (400 ng/l), 1 
g of RNA, 0.5 l RNasin (40 U), and 1 l MMLV-rt 
(200 U) in a total volume of 20 l. Thermal cycler 
program was: 95 ˚C for 5 min before addition of RNasin 
and reverse transcriptase, and incubation at 25 ˚C for 10 
min, 42 ˚C for 50 min and then  they were subjected to 
real time PCR examinations. PCR experiment was 
performed to assess the expression of selected key genes 
as mentioned above.  
All amplification reactions were performed in a total 
25µl volume using the iQ5 Optical System (Bio-Rad 
Laboratories Inc., Hercules, USA). Each well contained: 
1 µl cDNA, 1 µl primer (100 nM each primer), 12.5 µl 
2X Power SYBR Green PCR Master Mix and 10.5 µl 
RNAse/DNAse free water. Thermal cycling conditions 
were as follows: 1 cycle at 94˚C for 10 min, 40 cycles at 
95˚C for 15 sec, 56-62˚C for 30 sec, and 72˚C for 25 sec. 
Interpretation of the result was performed using the 
Pfaffle method and the CT values were normalized to the 
expression rate of GAPDH as a housekeeping gene 
(Pfaffl 2001). All reactions were performed in triplicate 
and negative control included in each experiment as well 
as internal positive control. 
Data analyzing 
One way ANOVA was performed for statistical analysis 
using SPSS version 18 following with Tukey’s Post Hoc 
Test.  A p value less than 0.05 was considered to 
statistical differences representation. MTT assays and 
Trypan blue exclusion tests were performed in at least 
five independent experiments and gene expression 
evaluation using real time RT-PCR performed in 
triplicate manner. 
 
Results 
Cytotoxicity assessment 
Trypan blue exclusion test and MTT assay were 
conducted to evaluate the cytotoxicity of carbenoxolone 
in MCF7and BT20 human breast cancer cells. As shown 
in Fig. 2, CBX treated cells led to growth inhibition in 
dose dependent manner (p < 0.05). 
 
Fig. 2. The Effects of CBX on growth inhibition of MCF7 and 
BT20 cells. Cells were exposed to the indicated concentration 
(50-1000µM) for 24 h (♦) and 48 h (□) in the case of MCF7 as 
well as for 24 h (▲) and 48 h (■) in the case of BT20. The 
number of viable cells was determined by Trypan blue exclusion 
test. Growth inhibition in each treatment was expressed as a 
percentage of the control. Each value represents the mean ± SE 
of at least five independent experiments. 
 
Table 1. Genes with corresponding primers which used for gene expression analysis 
Gene name Accession No. Sequence Product length 
GAPDH NM_002046.3 
F: 5’-AAGCTCATTTCCTGGTATGACAACG-3’ 
R: 5’-TCTTCCTCTTGTGCTCTTGCTGG-3’ 
126 
BCL2 NM_000633.2 
F: 5’-CATCAGGAAGGCTAGAGTTACC-3’ 
R: 5’-CAGACATTCGGAGACCACAC-3’ 
181 
AKT1 NM_005163.2 
F: 5’- CGCAGTGCCAGCTGATGAAG -3’ 
R: 5’- GTCCATCTCCTCCTCCTCCTG -3’ 
185 
CYCS NM_018947.4 
F: 5’- ACCTTCCATCTTGGCTAGTTGTG-3’ 
R: 5’- ATCGCTTGAGCCTGGGAAATAG-3’ 
129 
STAT5 NM_007315.3 
F: 5’- TCATCAGCAAGGAGCGAGAG-3’ 
R: 5’- TCAGGGAAAGTAACAGCAGAAAG-3’ 
196 
TP53 NM_001126114 
F: 5’-TCAACAAGATGTTTTGCCAACTG-3’ 
R: 5’-ATGTGCTGTGACTGCTTGTAGATG-3’ 
118 
F: Forward; R: Reverse 
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Fig. 3. Photomicrographs of MCF7 and BT20 cells were taken by a light microscope at a magnification of 40×. MCF7 and BT20 cells were 
treated by 150 µM of CBX. The death cells are shown by black arrows. Panel A represent untreated MCF7 cells versus CBX treated MCF7 
cells in panels B and C at exposure times of 24h and 48h respectively. Panel D represent untreated BT20 cells versus CBX treated BT20 
cells in panels E and F at exposure times of 24h and 48h respectively.  
As it shows, the growth of treated BT20 cells was 
affected notably, but in the case of MCF7 cells, anti-
proliferative effect of CBX was lower than previous 
cells. However, CBX also showed statistically 
significant cytotoxicity in the MCF cells. Additionally, 
the treated and untreated cells displayed distinct 
morphologic differences in normal and death cells 
number and appearance upon light microscopic 
examinations   (Fig. 3). Regarding the obtained data 
from MTT experiment as a standard colorimetric cell 
viability assay, IC50 were calculated as 150 M in both 
cells (Fig 4), which is relatively similar to obtained IC50 
from data of growth inhibition evaluation via Trypan 
blue exclusion test in Fig. 2.  In the view of statistics 
(mean ±SE of at least five independent experiments), 
reduction in number of cells was observed after 
treatment by 150 µM of CBX as same as reduction in 
total amount of extracted RNA in both cells (data not 
shown). Despite mild exacerbation in CBX mediated 
cytotoxicity in a time dependent manner, it was not 
statistically significant even at exposure time of 72 hr in 
both cell lines (data not shown).  
A 
B 
C 
D 
E 
F 
MCF7 Cells BT20 Cells 
24h 24h 
48h 48h 
Untreated cells Untreated cells 
Gap junctions in cancer cells 
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Fig. 4. Results of MTT assay for evaluation of cell viability. Cells 
were exposed to the indicated concentration of CBX (50-
1000µM) at exposure time of 24 h (♦) and 48 h (□) and also are 
repeated in the case of BT20 for mentioned concentrations and 
exposure times. As shown in this diagram, CBX in 150 µM of 
concentration could significantly suppress the production of 
formazan as reductive metabolite of MTT (3-(4, 5-
Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) in both 
cell lines. Each value represents the mean ± SE of at least five 
independent experiments. 
 
Gene expression analyses      
MCF7 and BT20 cells were incubated with CBX (150 
µM) for 24 h. Then expression levels of candidate genes 
which mentioned above were detected by using real time 
PCR and Interpretation of the results was performed 
using the Pfaffle method and finally the CT values of 
each gene were normalized to the expression behavior of 
GAPDH as a housekeeping gene. All reactions were 
performed in triplicate and negative control included in 
each experiment and then quantified as a view of SYBR 
Green emitted fluorescent intensity. 
We performed a quantitative PCR approach to assess the 
effect of carbenoxolone on the expression of apoptosis 
related genes BCL2 and CYSC , EGF pathway candidate 
genes AKT1and STAT5and finally TP53 as crucial gene 
the cell cycle control and a tumor suppressor gene which 
is involved in cancer preventing ( May, P. and May, E. 
1999). The mRNA expression of these genes versus 
GAPDH expression is illustrated in Figure 5. The 
respective ratio of expressed gene over GAPDH 
expression was used to represent gene expression 
changes and was demonstrated quantitatively in Fig. 5. 
Normalization of our data to the expression rate of 
GAPDH as a housekeeping gene, revealed significant 
down regulation of all mentioned genes in both type of 
cells but there was not significant changes among these 
candidate genes themselves. 
 
 
Fig. 5. Quantitative real time PCR assessments of CBX on 
MCF7 cells (Panel A) and BT20 cells (Panel B). Normalized 
relative expressions intensity ratio of the genes upon the 
expression of housekeeping GAPDH gene. All of the genes 
expressions are significant statistically upon GAPDH. The values 
were obtained as a view of SYBR Green emitted fluorescent 
intensity in triplicate experiments statistically (mean ± SEM).  
 
Discussion 
Although, various drugs have been proposed for the 
treatment of breast cancer, lack of deep knowledge about 
cancer biology and adverse side effects of routine 
anticancer drugs are obstacles of complete treatment. 
Consequently, many efforts are in progress to find new 
approaches to overcome cancer. Inhibition of gap 
junctions is one of these efforts and CBX is a prototypic 
inhibitor of them. However, in the case of CBX, total 
amount of extracted RNA decreased in treated group in 
both types of cells (data not shown) which could indicate 
the reduction of cell numbers after incubation with drug. 
It should be highlighted that MCF7 cells have more 
proliferative and progressive behavior, dependent on 
their EGF, progesterone and estrogen receptors. MTT 
assay revealed significant reduction in cell viability in 
BT20 cells (Fig. 4), while MCF7 did not show such 
effects due to mentioned supportive receptors in MCF7 
cells (Rulli, Antognelli et al. 2006). According to the 
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results, CBX inhibits MCF7 and BT20 cells growth and 
viability just in a dose dependent manner with 
IC50 values of 150 μM after 24 h of exposure. The anti-
ploriferative effects of CBX have been reported in other 
cancer cells (Kawashima et al. 2009). Apoptotic effects 
of CBX have been also reported in some types of cells 
(Pivato et al. 2006; Waddell et al. 2000). Among several 
mechanisms of action which have been proposed for 
pharmacological activity of CBX, induction of 
Mitochondrial Permeability Transition (MPT) and 
release of cytochrome c is prominent (Salvi et al. 2005; 
Pivato et al. 2006). Therefore, it can be considered as an 
apoptosis stimulating drug   (Isbrucker et al. 2006; Salvi 
et al. 2005). Due to structural similarity to 
glucocorticoids, CBX inhibits Hydroxysteroid 
dehydrogenases (HSD) in cancer cells and induces 
apoptosis via interaction with glucocorticoid and 
mineralocorticoid receptors (Greenstein et al. 2002; 
Voutsas et al. 2007). It seems that TP53 and CYCS genes 
as well as STAT1 gene down regulation are 
compensatory responses against anti-apoptotic genes 
down regulation which totally arise from stress oxidative 
effect of Carbenoxolone (Farczadi, Kaszas et al. 2002). 
AKT1 and BCL2 genes are anti-apoptotic down regulated 
genes with similar effect on cancer cells. Of these down 
regulated genes, the BCL2 gene encodes the bcl2 protein 
that involved in a wide variety of cellular activities such 
as homeostasis and tumorigenesis. The encoded protein 
is able to reduce the release of pro-apoptotic cytochrome 
c from mitochondria and block caspase activation. This 
suggests a cytoprotective and cell survival functionality 
for this gene as reported previously ( Karsan et al. 1996; 
Choi et al. 1995)  but as it mentioned, cytochrome c has 
been down regulated in CBX group, probably due to 
carbenoxolone stress oxidative effect (Salvi et al. 2005; 
Pivato et al. 2006) and BCL2  counter regulatory gene, 
was not able to be compensated. In the view of 
transcryptomics, it seems that Carbenoxolone affects 
cancer cell viability despite some ambiguous findings in 
cell viability and cytotoxicity assays.  Lewenstein and 
his co-workers provided the “Homologous Growth 
Control (HGC)”  theory approximately forty  years ago 
which talks about gap junctions' delirious role in 
carcinogenesis particularly in the case of gap junction 
intercellular communication(GJIC) between normal and 
cancer  cells (Cronier, Crespin et al. 2009) and CBX has 
confirmed inhibitory effects on gap junction-mediated 
intercellular communication (GJIC) particularly in 
attached cells as well (Winmill et al. 2003; Paraguassu-
Braga et al. 2003). Therefore we cannot establish a 
precise mechanism for CBX activity.  
 
Conclusion 
Breast cancer has emerged as a leading cause of cancer 
death in the world particularly in women. Unfortunately, 
the current therapeutic strategies are ineffective in some 
cases; hence, there exists an increasing demand for more 
effective therapies. We examined the CBX in this matter. 
In conclusion, based on the results obtained in this study, 
we suggest that CBX be favourable for in vivo 
applications; nevertheless further investigations are yet 
to be fulfilled to authenticate its in vivo usefulness. This 
obviously means that there is a novel relationship 
between cell-cell communications and inter-cellular 
cross talking, perhaps via gap junctions, at whom we 
propose that interestingly orchestrated biochemical 
machinery of cells may be related to some downstream 
cell signalling which may play a key role in development 
of cancer. On the other hand, the main question is 
remained: Are gap junctions friend or enemy? Therefore 
we propose evaluation of CBX effects on genetically 
modified cancer cell lines particularly in transcriptomics 
and functional genomics level using DNA chip 
technology.   
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